Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation

Autor: Michael Lowe, Lesley Murray, Alok Tyagi, George Gorrie, Sarah Miller, Krishna Dani, the NHS Greater Glasgow and Clyde Headache Service
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-9 (2022)
Druh dokumentu: article
ISSN: 1129-2369
1129-2377
DOI: 10.1186/s10194-022-01456-2
Popis: Abstract Background Calcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary headache centre. Methods This was a prospective clinical audit of all patients commenced on erenumab following a locally agreed pathway and criteria over a consecutive period. Patients received monthly erenumab 140 mg for 3 months. Data were collected prospectively at baseline and 3 months follow up. Results One hundred three patients were commenced on erenumab during the study period. Patients had tried a median of 7 previous prophylactics, including onabotulinum toxin A in 94%. At 3 months there was a reduction in median total (28 to 20, 29% reduction, p
Databáze: Directory of Open Access Journals
Externí odkaz: